Literature DB >> 30421102

Mexican rheumatology: where do we stand?

Carlos Pineda1, Hugo Sandoval2, Antonio Fraga-Mouret3.   

Abstract

The aim of this review was to provide an overall overview of the past, present, and future situations and main challenges that are facing Mexican Rheumatology as a medical subspecialty in the context of their national healthcare system, where a deficit of workforce at the national level coexists with a shortage of specialists in the less-developed southern states of the country and a great surplus of professionals within large metropolitan areas. We also analyzed the prevalence and burden of Rheumatic and Musculoskeletal Diseases (RMDs), the structural composition and distribution of Mexican Rheumatology, and the clinical profile of the Mexican Rheumatologist. Last, we examined comorbidities, education and training programs and one scenario for Mexican Rheumatology wherein the principal main threats and opportunities are determined.

Entities:  

Keywords:  Health services; Medical staff; Mexico; Musculoskeletal diseases; Rheumatology

Mesh:

Year:  2018        PMID: 30421102     DOI: 10.1007/s00296-018-4198-7

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  44 in total

1.  Ultrasound in rheumatology. The Mexican experience.

Authors:  C Pineda; E Filippucci; M Chávez-López; C Hernández-Díaz; C Moya; L Ventura; W Grassi
Journal:  Clin Exp Rheumatol       Date:  2008 Sep-Oct       Impact factor: 4.473

2.  [Appropriate use of non-steroidal anti-inflammatory drugs in rheumatology: guidelines from the Spanish Society of Rheumatology and the Mexican College of Rheumatology].

Authors:  Gerardo Bori Segura; Blanca Hernández Cruz; Milena Gobbo; Angel Lanas Arbeloa; Mario Salazar Páramo; Leobardo Terán Estrada; José Federico Díaz González; Rolando Espinosa Morales; Federico Galván Villegas; Luis Alberto García Rodríguez; José María Alvaro-Gracia Álvaro; Hilario Avila Armengol; Loreto Carmona; Javier Rivera Redondo; Lucio Ventura Ríos
Journal:  Reumatol Clin       Date:  2009-02-28

Review 3.  Regulatory and clinical considerations for biosimilar oncology drugs.

Authors:  Charles L Bennett; Brian Chen; Terhi Hermanson; Michael D Wyatt; Richard M Schulz; Peter Georgantopoulos; Samuel Kessler; Dennis W Raisch; Zaina P Qureshi; Z Kevin Lu; Bryan L Love; Virginia Noxon; Laura Bobolts; Melissa Armitage; John Bian; Paul Ray; Richard J Ablin; William J Hrushesky; Iain C Macdougall; Oliver Sartor; James O Armitage
Journal:  Lancet Oncol       Date:  2014-11-24       Impact factor: 41.316

4.  Defining Quality of Rheumatologic Care: Mexico.

Authors:  Carlos Pineda; Hugo Sandoval
Journal:  J Clin Rheumatol       Date:  2017-06       Impact factor: 3.517

5.  Biosimilar drugs in Mexico: position of the Mexican College of Rheumatology, 2012.

Authors:  Rolando Espinosa Morales; Alejandro Díaz Borjón; Leonor Adriana Barile Fabris; Jorge Antonio Esquivel Valerio; Gabriel Medrano Ramírez; César Alejandro Arce Salinas; Eduardo Rubén Barreira Mercado; Mario Humberto Cardiel Ríos; Efraín Díaz Jouanen; Francisco Javier Flores Murrieta; Antonio Fraga Mouret; Mario Alberto Garza Elizondo; Miguel Luján Estrada; Francisco José Muñoz Barradas; Juan Osvaldo Talavera Piña; Olga Lidia Vera Lastra
Journal:  Reumatol Clin       Date:  2013-02-08

Review 6.  The Regulation of Biosimilars in Latin America.

Authors:  Ricardo Garcia; Denizar Vianna Araujo
Journal:  Curr Rheumatol Rep       Date:  2016-03       Impact factor: 4.592

7.  Factors associated with treatment of osteoarthritis: Analysis of a COPCORD study in Nuevo León, México.

Authors:  Alexia Estefanía Hernández-Cáceres; Jacqueline Rodriguez-Amado; Ingris Peláez-Ballestas; David Vega-Morales; Mario Alberto Garza-Elizondo
Journal:  Reumatol Clin       Date:  2015-01-24

8.  Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology.

Authors:  Ingris Peláez-Ballestas; Luz Helena Sanin; José Moreno-Montoya; José Alvarez-Nemegyei; Rubén Burgos-Vargas; Mario Garza-Elizondo; Jacqueline Rodríguez-Amado; Maria-Victoria Goycochea-Robles; Marco Madariaga; Jorge Zamudio; Natalia Santana; Mario H Cardiel
Journal:  J Rheumatol Suppl       Date:  2011-01

9.  [Renal involvement in systemic sclerosis].

Authors:  Luis J Jara; Antonio Barrera
Journal:  Reumatol Clin       Date:  2008-12-10

10.  Objectives and methodology of BIOBADASER phase iii.

Authors:  Carlos Sanchez-Piedra; M Victoria Hernández Miguel; Javier Manero; Rosa Roselló; Jesús Tomás Sánchez-Costa; Carlos Rodríguez-Lozano; Cristina Campos; Eduardo Cuende; Jesús Carlos Fernández-Lopez; Sagrario Bustabad; Raquel Martín Domenech; Eva Pérez-Pampín; Javier Del Pino-Montes; Ana Milena Millan-Arciniegas; Federico Díaz-González; Juan Jesús Gómez-Reino
Journal:  Reumatol Clin (Engl Ed)       Date:  2017-09-19
View more
  3 in total

1.  Current status of the rheumatologists' workforce in Latin America: a PANLAR collaborative study.

Authors:  Daniel Gerardo Fernández-Ávila; Daniela Patino-Hernandez; Sergio Kowalskii; Alfredo Vargas-Caselles; Ana Maria Sapag; Antonio Cachafeiro-Vilar; Lucia Meléndez-Muñoz; Carlos Santiago-Pastelín; Cesar Graf; Chayanne Rossetto; Daniel Palleiro; Daniela Trincado; Diana Fernández-Ávila; Dina Arrieta; Gil Reyes; Jossiel Then Baez; Manuel F Ugarte-Gil; Mario Cardiel; Nelly Colman; Nilmo Chávez; Paula I Burgos; Ruben Montúfar; Sayonara Sandino; Yurilis Fuentes-Silva; Enrique R Soriano
Journal:  Clin Rheumatol       Date:  2021-01-15       Impact factor: 2.980

2.  Systemic lupus erythematosus, a leading cause of death in young Mexican females: a nationwide population-based study, 2000-2020.

Authors:  Ivet Etchegaray-Morales; Claudia Mendoza-Pinto; Pamela Munguía-Realpozo; Ángel David Osorio-Peña; Sandra Ibañez-Ovando; Carlos Pineda; Mario García-Carrasco
Journal:  Rheumatol Int       Date:  2022-06-08       Impact factor: 3.580

3.  Global Rural and Remote Patients With Rheumatoid Arthritis: A Systematic Review.

Authors:  Emilie Pianarosa; Kelsey Chomistek; Ralph Hsiao; Salman Anwar; Valerie Umaefulam; Glen Hazlewood; Cheryl Barnabe
Journal:  Arthritis Care Res (Hoboken)       Date:  2022-02-22       Impact factor: 5.178

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.